Cargando…

Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI

Blood based traumatic brain injury (TBI) biomarkers offer additional diagnostic, therapeutic, and prognostic utility. While adult studies are robust, the pediatric population is less well studied. We sought to determine whether plasma osteopontin (OPN) and S100B alone or in combination predict morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwell, Laura S., Wali, Bushra, Xiang, Yijin, Alawieh, Ali, Sayeed, Iqbal, Reisner, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452243/
https://www.ncbi.nlm.nih.gov/pubmed/37626664
http://dx.doi.org/10.3390/biomedicines11082167
_version_ 1785095620597383168
author Blackwell, Laura S.
Wali, Bushra
Xiang, Yijin
Alawieh, Ali
Sayeed, Iqbal
Reisner, Andrew
author_facet Blackwell, Laura S.
Wali, Bushra
Xiang, Yijin
Alawieh, Ali
Sayeed, Iqbal
Reisner, Andrew
author_sort Blackwell, Laura S.
collection PubMed
description Blood based traumatic brain injury (TBI) biomarkers offer additional diagnostic, therapeutic, and prognostic utility. While adult studies are robust, the pediatric population is less well studied. We sought to determine whether plasma osteopontin (OPN) and S100B alone or in combination predict mortality, head Computed tomography (CT) findings, as well as 6-month functional outcomes after TBI in children. This is a prospective, observational study between March 2017 and June 2021 at a tertiary pediatric hospital. The sample included children with a diagnosed head injury of any severity admitted to the Emergency Department. Control patients sustained trauma-related injuries and no known head trauma. Serial blood samples were collected at admission, as well as at 24, 48, and 72 h. Patient demographics, acute clinical symptoms, head CT, and 6-month follow-up using the Glasgow outcome scale, extended for pediatrics (GOSE-Peds), were also obtained. The cohort included 460 children (ages 0 to 21 years) and reflected the race and sex distribution of the population served. Linear mixed effect models and logistic regressions were utilized to evaluate the trajectory of biomarkers over time and predictors of dichotomous outcomes. Both OPN and S100B correlated with injury severity based on GCS. S100B and OPN showed lower AUC values (0.59) in predicting positive head CT. S100B had the largest AUC (0.87) in predicting mortality, as well as 6-month outcomes (0.85). The combination of the two biomarkers did not add meaningfully to the model. Our findings continue to support the utility of OPN as a marker of injury severity in this population. Our findings also show the importance of S100B in predicting mortality and 6-month functional outcomes. Continued work is needed to examine the influence of age-dependent neurodevelopment on TBI biomarker profiles in children.
format Online
Article
Text
id pubmed-10452243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104522432023-08-26 Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI Blackwell, Laura S. Wali, Bushra Xiang, Yijin Alawieh, Ali Sayeed, Iqbal Reisner, Andrew Biomedicines Article Blood based traumatic brain injury (TBI) biomarkers offer additional diagnostic, therapeutic, and prognostic utility. While adult studies are robust, the pediatric population is less well studied. We sought to determine whether plasma osteopontin (OPN) and S100B alone or in combination predict mortality, head Computed tomography (CT) findings, as well as 6-month functional outcomes after TBI in children. This is a prospective, observational study between March 2017 and June 2021 at a tertiary pediatric hospital. The sample included children with a diagnosed head injury of any severity admitted to the Emergency Department. Control patients sustained trauma-related injuries and no known head trauma. Serial blood samples were collected at admission, as well as at 24, 48, and 72 h. Patient demographics, acute clinical symptoms, head CT, and 6-month follow-up using the Glasgow outcome scale, extended for pediatrics (GOSE-Peds), were also obtained. The cohort included 460 children (ages 0 to 21 years) and reflected the race and sex distribution of the population served. Linear mixed effect models and logistic regressions were utilized to evaluate the trajectory of biomarkers over time and predictors of dichotomous outcomes. Both OPN and S100B correlated with injury severity based on GCS. S100B and OPN showed lower AUC values (0.59) in predicting positive head CT. S100B had the largest AUC (0.87) in predicting mortality, as well as 6-month outcomes (0.85). The combination of the two biomarkers did not add meaningfully to the model. Our findings continue to support the utility of OPN as a marker of injury severity in this population. Our findings also show the importance of S100B in predicting mortality and 6-month functional outcomes. Continued work is needed to examine the influence of age-dependent neurodevelopment on TBI biomarker profiles in children. MDPI 2023-08-01 /pmc/articles/PMC10452243/ /pubmed/37626664 http://dx.doi.org/10.3390/biomedicines11082167 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blackwell, Laura S.
Wali, Bushra
Xiang, Yijin
Alawieh, Ali
Sayeed, Iqbal
Reisner, Andrew
Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title_full Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title_fullStr Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title_full_unstemmed Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title_short Prognostic Value of Plasma Biomarkers S100B and Osteopontin in Pediatric TBI: A Prospective Analysis Evaluating Acute and 6-Month Outcomes after Mild to Severe TBI
title_sort prognostic value of plasma biomarkers s100b and osteopontin in pediatric tbi: a prospective analysis evaluating acute and 6-month outcomes after mild to severe tbi
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452243/
https://www.ncbi.nlm.nih.gov/pubmed/37626664
http://dx.doi.org/10.3390/biomedicines11082167
work_keys_str_mv AT blackwelllauras prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi
AT walibushra prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi
AT xiangyijin prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi
AT alawiehali prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi
AT sayeediqbal prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi
AT reisnerandrew prognosticvalueofplasmabiomarkerss100bandosteopontininpediatrictbiaprospectiveanalysisevaluatingacuteand6monthoutcomesaftermildtoseveretbi